Why carry out this study? (1–2 points for background; 1 point for hypothesis)

While biologics have revolutionized the management of psoriasis, response to treatment varies, and efficacy may decline over time, resulting in treatment discontinuation

Little is known about relative real-world performance of biologic agents for psoriasis, particularly after guselkumab, an interleukin-23 inhibitor, was approved for psoriasis in 2017

This study aimed to describe real-world persistence, reinitiation, and possible remission of patients with psoriasis initiated on guselkumab, adalimumab, secukinumab, and ixekizumab using administrative claims data

What was learned from the study? (1 point for conclusions; 1–2 points for what was learned)

Guselkumab relative to other biologics showed trends toward better persistence and higher remission rates

Identification of patients who may have entered remission suggests potential for disease modification with existing biologics